camrelizumab + famitinib

Camrelizumab + famitinib is a combination therapy consisting of camrelizumab, a humanized monoclonal antibody targeting programmed cell death protein 1 (PD-1), and famitinib, an oral small molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor (PDGFR), and c-Kit. Camrelizumab acts as an immune checkpoint inhibitor, enhancing T-cell mediated antitumor immunity by blocking the PD-1 pathway. Famitinib exerts antiangiogenic and antiproliferative effects by inhibiting multiple receptor tyrosine kinases involved in tumor angiogenesis and proliferation. The combination has demonstrated synergistic antitumor activity in several advanced or metastatic cancers—including non-small cell lung cancer (NSCLC), urothelial carcinoma, renal cell carcinoma, thyroid cancer, triple-negative breast cancer, and melanoma—by modulating the tumor microenvironment through dual blockade of immune suppression and angiogenesis pathways[1][3][4][5][6].